Ruthenium (II) polypyridyl complexes form a vast family of molecules characterized by their
finely tuned photochemical and photophysical properties. Their ability to undergo excited …

To investigate the potential of tumor-targeting photoactivated chemotherapy, a chiral
ruthenium-based anticancer warhead, Λ/Δ-[Ru (Ph2phen) 2 (OH2) 2] 2+, was conjugated to …

Lung cancer is the most common cause of cancer-related deaths worldwide. More efficient
treatments are desperately needed. For decades, the success of platinum-based anticancer …

Photoactivated chemotherapy (PACT) is a promising cancer treatment modality that kills
cancer cells via photochemical uncaging of a cytotoxic drug. Most ruthenium‐based …

Both ruthenium-containing complexes and 8-quinolinoline compounds have emerged as a
potential novel agent for malignant tumor therapy. Here, three triphenylphosphine ruthenium …

Ruthenium (II) polypyridyl complexes (RPCs) are gaining momentum in photoactivated
chemotherapy (PACT), thanks to the possibility of overcoming the classical reliance on …

The growing number of cancer cases requires the development of new approaches for
treatment. A therapy that has attracted the special attention of scientists is photodynamic …

The versatile and tunable ligand-exchange dynamics in ruthenium (II)-polypyridyl
complexes imposed by the modulation of the steric and electronic effects of the coordinated …

Photoactivable chemotherapy (PACT) using metallic complexes provides spatiotemporal
selectivity over drug activation for targeted anticancer therapy. However, the poor absorption …

Ruthenium (II) complexes containing diimine ligands have contributed to the development of
agents for photoactivated chemotherapy. Several approaches have been used to obtain …